Article Details
Retrieved on: 2018-04-23 18:52:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Both companies are developing drugs that recruit key components of the ubiquitin-proteasome system to targeted proteins, leading to the proteins' destruction. Both have large partnerships with pharma companies. <b>Atlas Venture</b> launched its own company in this area, Kymera Therapeutics, late last year ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here